

March 30, 2017

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

**Scrip Code: NEULANLAB
Series: EQ**

Dear Sir(s),

**Sub: Clarification on the published news
Ref: News Item which appeared on "CNBC TV18" dated March 30, 2017 captioned
"Neuland Labs close to acquiring intermediates, API facility"**

We refer to your letter dated March 30, 2017 regarding clarification on the above referred news item which appeared on 'CNBC TV18'.

In this regard, we would like to provide clarification on the news item in detail as below:

- a. **Whether such negotiations were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations till date.**

As a part of Company's growth strategy, it is continuously looking for opportunities to augment its capacity. Amongst all such opportunities that the Company is presently evaluating, it would clarify that at this stage there is no such facility/transaction which has been finalised and the Company has not entered into any binding definite agreement. Should the Company conclude anything material, it will be notified to Stock Exchanges



: 2 :

- b. Whether you/Company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading? If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

The Company would like to inform you that it has been complying with Regulation 30 of the SEBI (LODR) Regulations, 2015 ("Listing Regulations") and relevant price sensitive information has been disclosed to the Stock Exchanges from time to time, within the stipulated timelines.

It would further clarify that there is no such information withheld by the Company, which is price sensitive in nature and required to be disclosed to the Stock Exchanges as on date.

This is for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

